

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

22-107

MEDICAL REVIEW(S)

CLINICAL REVIEW

Application Type NDA
Submission Number 22-107
Submission Code SN000

Letter Date March 19, 2007
Stamp Date March 20, 2007
PDUFA Goal Date January 20, 2008

Reviewer Name Shen Xiao, M.D., Ph.D.
Review Completion Date October 2, 2007

Established Name Aliskiren/Hydrochlorothiazide
(Proposed) Trade Name Tekturna HCT®
Therapeutic Class Antihypertensive (Renin inhibitor
combined with diuretics)
Applicant Novartis

Priority Designation S

Formulation Oral tablet
Dosing Regimen Aliskiren/Hydrochlorothiazide:
150/12.5 mg, 150/25mg,
300/12.5mg, and 300/25mg

Indication Treatment of hypertension
Intended Population Adult patients with hypertension

Table of Contents

1	EXECUTIVE SUMMARY	14
1.1	RECOMMENDATION ON REGULATORY ACTION.....	14
1.2	RECOMMENDATION ON POSTMARKETING ACTIONS	14
1.2.1	Risk Management Activity	14
1.2.2	Required Phase 4 Commitments	14
1.2.3	Other Phase 4 Requests.....	14
1.3	SUMMARY OF CLINICAL FINDINGS.....	15
1.3.1	Brief Overview of Clinical Program	15
1.3.2	Efficacy.....	15
1.3.3	Safety.....	17
1.3.4	Dosing Regimen and Administration	17
1.3.5	Drug-Drug Interactions.....	18
1.3.6	Special Populations.....	18
2	INTRODUCTION AND BACKGROUND.....	18
2.1	PRODUCT INFORMATION	18
2.2	CURRENTLY AVAILABLE TREATMENT FOR INDICATIONS	19
2.3	AVAILABILITY OF PROPOSED ACTIVE INGREDIENT IN THE UNITED STATES	19
2.4	IMPORTANT ISSUES WITH PHARMACOLOGICALLY RELATED PRODUCTS.....	19
2.5	PRESUBMISSION REGULATORY ACTIVITY	20
2.6	OTHER RELEVANT BACKGROUND INFORMATION	20
3	SIGNIFICANT FINDINGS FROM OTHER REVIEW DISCIPLINES	20
3.1	CMC (AND PRODUCT MICROBIOLOGY, IF APPLICABLE).....	20
3.2	ANIMAL PHARMACOLOGY/TOXICOLOGY	20
4	DATA SOURCES, REVIEW STRATEGY, AND DATA INTEGRITY.....	21
4.1	SOURCES OF CLINICAL DATA	21
4.2	TABLES OF CLINICAL STUDIES	21
4.3	REVIEW STRATEGY	23
4.4	DATA QUALITY AND INTEGRITY	23
4.5	COMPLIANCE WITH GOOD CLINICAL PRACTICES	23
4.6	FINANCIAL DISCLOSURES	24
5	CLINICAL PHARMACOLOGY.....	24
5.1	PHARMACOKINETICS.....	24
5.2	PHARMACODYNAMICS.....	25
5.3	EXPOSURE-RESPONSE RELATIONSHIPS	25
6	INTEGRATED REVIEW OF EFFICACY.....	26
6.1	INDICATION	26
6.1.1	Methods.....	26
6.1.2	General Discussion of Endpoints.....	26
6.1.3	Study Design.....	27

Clinical Review
Shen Xiao, M.D., Ph.D.
NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

6.1.4 Efficacy findings.....	27
6.1.5 Clinical Microbiology.....	43
6.1.6 Efficacy Conclusions.....	43
7 INTEGRATED REVIEW OF SAFETY.....	44
7.1 METHODS AND FINDINGS.....	44
7.1.1 Deaths.....	45
7.1.2 Serious Adverse Events.....	48
7.1.3 Dropouts and Other Significant Adverse Events.....	61
7.1.4 Other Search Strategies.....	74
7.1.5 Common Adverse Events.....	74
7.1.6 Less Common Adverse Events.....	78
7.1.7 Laboratory Findings.....	78
7.1.8 Vital Signs.....	85
7.1.9 Electrocardiograms (ECGs).....	86
7.1.10 Immunogenicity.....	86
7.1.11 Human Carcinogenicity.....	86
7.1.12 Special Safety Studies.....	87
7.1.13 Withdrawal Phenomena and/or Abuse Potential.....	87
7.1.14 Human Reproduction and Pregnancy Data.....	87
7.1.15 Assessment of Effect on Growth.....	87
7.1.16 Overdose Experience.....	88
7.1.17 Postmarketing Experience.....	88
7.2 ADEQUACY OF PATIENT EXPOSURE AND SAFETY ASSESSMENTS.....	88
7.2.1 Description of Primary Clinical Data Sources (Populations Exposed and Extent of Exposure) Used to Evaluate Safety.....	88
7.2.2 Description of Secondary Clinical Data Sources Used to Evaluate Safety.....	92
7.2.3 Adequacy of Overall Clinical Experience.....	93
7.2.4 Adequacy of Special Animal and/or In Vitro Testing.....	93
7.2.5 Adequacy of Routine Clinical Testing.....	93
7.2.6 Adequacy of Metabolic, Clearance, and Interaction Workup.....	93
7.2.7 Adequacy of Evaluation for Potential Adverse Events for Any New Drug and Particularly for Drugs in the Class Represented by the New Drug; Recommendations for Further Study.....	93
7.2.8 Assessment of Quality and Completeness of Data.....	93
7.2.9 Additional Submissions, Including Safety Update.....	93
7.3 SUMMARY OF SELECTED DRUG-RELATED ADVERSE EVENTS, IMPORTANT LIMITATIONS OF DATA, AND CONCLUSIONS.....	94
7.4 GENERAL METHODOLOGY.....	94
7.4.1 Pooling Data Across Studies to Estimate and Compare Incidence.....	94
7.4.2 Explorations for Predictive Factors.....	94
7.4.3 Causality Determination.....	95
8 ADDITIONAL CLINICAL ISSUES.....	95
8.1 DOSING REGIMEN AND ADMINISTRATION.....	95
8.2 DRUG-DRUG INTERACTIONS.....	95

Clinical Review
Shen Xiao, M.D., Ph.D.
NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

8.3	SPECIAL POPULATIONS.....	95
8.4	PEDIATRICS.....	95
8.5	ADVISORY COMMITTEE MEETING.....	96
8.6	LITERATURE REVIEW.....	96
8.7	POSTMARKETING RISK MANAGEMENT PLAN.....	96
8.8	OTHER RELEVANT MATERIALS.....	96
9	OVERALL ASSESSMENT.....	96
9.1	CONCLUSIONS.....	96
9.2	RECOMMENDATION ON REGULATORY ACTION.....	97
9.3	RECOMMENDATION ON POSTMARKETING ACTIONS.....	97
9.3.1	Risk Management Activity.....	97
9.3.2	Required Phase 4 Commitments.....	97
9.3.3	Other Phase 4 Requests.....	97
9.4	LABELING REVIEW.....	97
9.5	COMMENTS TO APPLICANT.....	97
10	APPENDICES.....	98
10.1	REVIEW OF INDIVIDUAL STUDY REPORTS.....	98
10.1.1	Study 0014: Effect of the combination of Aliskiren and Hydrochlorothiazide on daytime systolic blood pressure measured by 24-Hour Ambulatory Blood Pressure Monitoring Following Once-a-Day Administration of 150mg of Aliskiren alone and in combination with 25 mg Hydrochlorothiazide in Patients with Mild to Moderate Hypertension.....	98
10.1.2.	Study 2204: An 8-week, double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension.....	109
10.1.3.	Study 2302: 12 month, randomized, open-label, multicenter, study to assess the long term safety of aliskiren 150 mg alone and 300 mg alone or with the optional addition of hydrochlorothiazide (12.5 mg or 25 mg) in patients with essential hypertension..	121
10.1.4.	Study 2302 E1: A 4 month extension to a 12 month, randomized, open label, multicenter, study to assess the long term safety of aliskiren 150 mg alone and 300 mg alone or with the optional addition of hydrochlorothiazide (12.5 mg or 25 mg) in patients with essential hypertension.....	126
10.1.5.	Study 2303: An eight-week, randomized, double-blind, multi-center, active controlled, parallel group study to evaluate the safety and efficacy of an aliskiren based regimen compared to a lisinopril based regimen in patients with uncomplicated severe hypertension.....	129
10.1.6.	Study 2306: A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing aliskiren to ramipril with optional addition of hydrochlorothiazide, followed by a 4 week double-blind, randomized, placebo-controlled withdrawal in patients with essential hypertension.....	132
10.1.7.	Study 2309: A 12-week randomized double-blind parallel group study to evaluate the efficacy and safety of the combination of aliskiren with HCTZ compared to	

Clinical Review
Shen Xiao, M.D., Ph.D.
NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

irbesartan or amlodipine with HCTZ or HCTZ alone in hypertensive patients with BMI ≥ 30 kg/m ² not adequately responsive to HCTZ 25 mg.....	137
10.1.8 Study 1202: Long-term study with SPP100 (aliskiren) in patients with essential hypertension.....	143
10.1.9 Study 2331: An eight week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren/valsartan/HCTZ (300/320/25 mg), compared to the combinations of aliskiren/HCTZ (300/25 mg) and valsartan/HCTZ (320/25 mg) in patients with essential hypertension not adequately responsive to HCTZ 25 mg.....	149
10.2 LABELING REVIEW	154
11 REFERENCES.....	154

List of Tables

Table 1: Studies Supporting Efficacy and Safety in Hypertension.....	22
Table 2: Ongoing Studies to Support Efficacy and Safety in Hypertension.....	23
Table 3: Mean plus/minus SD (CV%) pharmacokinetic parameters of aliskiren at steady-state following single daily oral administration of 300 mg aliskiren alone (study day 15) or in combination with 25 mg HCTZ daily oral administration (study day 19)	25
Table 4: Mean plus/minus SD (CV%) pharmacokinetic parameters of HCTZ at steady-state following single daily oral administration of 25 mg HCTZ alone (study day 4) or in combination with 300 mg aliskiren daily oral administration (study day 19)	25
Table 5: Sponsor's change from baseline in mean sitting diastolic blood pressure (mmHg) at endpoint (ITT population).....	28
Table 6: Sponsor's change from baseline in mean sitting systolic blood pressure (mmHg) at endpoint (ITT population).....	29
Table 7: Responder rates (%) and control rates (%) at endpoint (primary ITT population – Study 2204)	33
Table 8: Summary statistics for Plasma Renin Activity by treatment group and visit (ITT population)	33
Table 9: Summary of studies providing long-term efficacy data	35
Table 10: Mean change from baseline in msDBP and msSBP (mm Hg) (longterm, open-label) (Study 2302, open-label ITT population)	36
Table 11: Change from baseline in mean sitting diastolic blood pressure during the entire study (All extension population)	36
Table 12: Change from baseline in mean sitting systolic blood pressure during the entire study (All extension population)	36
Table 13: Mean change from baseline in msDBP and msSBP at Week 26 endpoint in active-controlled treatment period (Study 2306 – ITT population).....	37
Table 14: Change from baseline to endpoint in msDBP by age group (primary ITT population – Study 2204).....	37
Table 15: Change from baseline to endpoint in msSBP by age group (primary ITT population – Study 2204).....	38
Table 16: Change from baseline to endpoint in msDBP by gender (primary ITT population – Study 2204).....	38
Table 17: Change from baseline to endpoint in msSBP by gender (primary ITT population – Study 2204).....	39
Table 18: Change from baseline for msDBP at endpoint in pooled treatment groups by obesity (Group A: short term, double-blind, placebo controlled studies, ITT population).....	39
Table 19: Change from baseline for msSBP at endpoint in pooled treatment groups by obesity (Group A: short term, double-blind, placebo controlled studies, ITT population).....	40
Table 20: Changes from baseline to endpoint in msDBP and msSBP in aliskiren, HCTZ, and the combination groups by race in Study 2204.....	41
Table 21: Summary of two active-controlled studies	41
Table 22: Mean change in sitting BP at Week 8 endpoint (ITT population – Study 2309)	42

Table 23: Changes from baseline in mean sitting diastolic blood pressure (msDBP, mmHg) at double blind visit by randomized treatment group in Study CSPP100A2303 (ITT population)	43
Table 24: Changes from baseline in mean sitting systolic blood pressure (msSBP, mmHg) at double-blind visit by randomized treatment group in Study 2303 (ITT population)	43
Table 25: Summary of short term placebo controlled and active controlled studies	44
Table 26: Summary of studies providing long-term safety data	45
Table 27: Deaths in all completed and ongoing studies (safety population)	48
Table 28: Number (%) of patients with serious adverse events in placebo controlled studies by primary system organ class (Study 2204, safety population)	49
Table 29: Number (%) of patients with serious adverse events in short term controlled studies by primary system organ class (safety population)	50
Table 30: Serious adverse events in long-term, open-label studies by primary system organ class (safety population)	51
Table 31: Serious adverse events in long-term, double-blind studies by primary system organ class (safety population)	51
Table 32: Overall profile of dropout rates in short-term placebo controlled studies	61
Table 33: Overall profile of dropout rates in short-term active controlled studies	62
Table 34: Overall profile of dropout rates in long-term open labeled studies	62
Table 35: Overall profile of dropout rates in long-term double blind studies	62
Table 36: Summary of adverse events associated with dropouts in short-term, placebo-controlled studies	63
Table 37: Summary of adverse events associated with dropouts in short-term, controlled studies	65
Table 38: Summary of adverse events associated with dropouts in long-term, open-label studies	67
Table 39: Summary of adverse events associated with dropouts in long-term, double-blinded studies	69
Table 40: Summary of potassium, BUN and creatinine in short-term placebo-controlled studies (safety population)	70
Table 41: Summary of potassium, BUN and creatinine in short-term controlled studies (safety population)	71
Table 42: Summary of potassium, BUN, and creatinine in long-term open-label studies (safety population)	71
Table 43: Summary of potassium, BUN, and creatinine in long-term double-blind studies (safety population)	71
Table 44: Incidence rate of cough in different studies	72
Table 45: Changes of hemoglobin and hematocrit from baseline in short-term active controlled studies	72
Table 46: Summary of incidence rates of gout, nephrolithiasis and changes of uric acid from baseline	73
Table 47: Number (%) of patients with common AEs ($\geq 2\%$ for any treatment group) in short-term placebo-controlled studies (safety population)	75
Table 48: Number (%) of patients with most frequent AEs ($\geq 2\%$ for any group) in short term, controlled studies (safety population)	76

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

Table 49: Number (%) of patients with most frequent AEs ($\geq 2\%$ for any treatment group) in long-term open-label studies (safety population)	77
Table 50: Number (%) of patients with most frequent AEs ($\geq 2\%$ for any treatment group) in long-term double-blind studies (safety population)	77
Table 51: Changes from Baseline in Hemoglobin (g/L) in short-term placebo-controlled, short-term active controlled, long-term open labeled, and long-term double-blind studies	79
Table 52: Summary of changes in potassium, sodium, calcium, uric acid, BUN, and creatinine for placebo, aliskiren and HCTZ monotherapy, and combination therapy in short-term controlled studies (safety population)	80
Table 53: Changes of clinical chemistry parameters in long-term open-label studies	81
Table 54: Criteria for notable laboratory values	82
Table 55: Summary of potassium, BUN and creatinine by specified criteria –in short-term placebo-controlled studies (safety population)	83
Table 56: Summary of potassium, BUN and creatinine by specified criteria –in short-term controlled studies (safety population)	83
Table 57: Summary of potassium, BUN, and creatinine by specified criteria in long-term open-label studies (safety population)	84
Table 58: Summary of potassium, BUN, and creatinine by specified criteria in long-term double-blind studies (safety population)	84
Table 59: Incidence of orthostatic blood pressure change in short-term placebo-controlled studies (safety population)	85
Table 60: Incidence of orthostatic blood pressure change in short-term controlled studies (safety population)	85
Table 61: Number (%) of patients with orthostatic blood pressure changes in long-term open-label studies (safety population)	86
Table 62: Number (%) of patients with orthostatic blood pressure changes in long-term double-blind studies (safety population)	86
Table 63: Demographics in the short-term placebo-controlled study (Study 2204, 8-week study)	88
Table 64: Demographics in active-controlled studies (Studies 2303 and 2309, 8-week and 12-week studies)	89
Table 65: Demographics in long-term open-label studies (Studies 2302 and 2302E1, 12-month study)	90
Table 66: Demographics in long-term double-blind study (Study 2306, 26-week study)	90
Table 67: Patient disposition and exposure in short-term controlled Study 2204, Study 2309, and Study 2303 (randomized populations)	91
Table 68: Patient disposition and exposure in open-label long-term Study 2302 and Study 2302E1 (open-label population) and active-controlled long-term Study 2306 (randomized population)	92
Table 69: Baseline Characteristics in study 0014	103
Table 70: Course of day-time ambulatory systolic blood pressure (from visit 2 to visit 4) in study 0014	104
Table 71: Course of daytime ambulatory diastolic blood pressure (from visit 2 to visit 4) in study 0014	104
Table 72: Course of night-time ambulatory blood pressure (from visit 2 to visit 4) in study 0014	105

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

Table 73: Cuff blood pressure measurement in study 0014	105
Table 74: Plasma Renin Activity Following 150 mg of aliskiren- (ITT Population) in study 0014	106
Table 75: Plasma Renin Activity following 150 mg of aliskiren or 150 mg aliskiren + 25 mg hydrochlorothiazide - (ITT Population) in study 0014	106
Table 76: Plasma concentrations of aliskiren following 150 mg of aliskiren- (ITT Population) in study 0014	106
Table 77: Display of Adverse Events by Subject in study 0014.....	107
Table 78: Changes of clinically relevant laboratory parameters in study 0014.....	108
Table 79:Disposition of Patients in Study 2204	113
Table 80: Baseline characteristics in study 2204	113
Table 81: Change from Baseline in DBP at 8 Weeks LOCF in Study 2204	115
Table 82: Change from Baseline in SBP at 8 Weeks LOCF in Study 2204	116
Table 83: Change from Baseline in DBP by Region in Study 2204.....	117
Table 84: Placebo-corrected Change from Baseline in DBP by Gender in Study 2204.....	117
Table 85: Rates of Deaths, SAEs, and Discontinuations in Study 2204.....	118
Table 86: Adverse Events $\geq 2\%$ in Any Group in Study 2204	119
Table 87: Change from Baseline in Selected Lab Values in Study 2204	120
Table 88: Shift Table Changes (Extreme Values) for Selected Lab Tests in Study 2204	120
Table 89: Summary of blood pressure results at Visit 10 (final visit, Month 11/12) of the open label period in Study 2302	123
Table 90: Comparison between treatment groups for change from Month 11 (Visit 10) in msDBP and msSBP at Endpoint of the randomized withdrawal period in study 2302	123
Table 91: Rates of Death, SAEs, and AE Discontinuations in study 2302	124
Table 92: Incidence rate of common adverse events ($\geq 1\%$) in order of frequency during high dose combination therapy Aliskiren/HCTZ 300/25 mg (All extension population) in Study 2302 E1	127
Table 93: Incidence of serious adverse events including death by primary system organ-class and preferred term during the high dose combination therapy Aliskiren/HCTZ 300/25 mg (All extension population) in study 2302 E1	128
Table 94: Change of uric acid from baseline in the extension of study.....	128
Table 95: Number of patients who received the actual treatment dose regimen during the double-blind period (randomized population) in study 2303.....	130
Table 96: Number (%) of patients with AEs (at least 2% in total) by primary system organ class during the double-blind period (Safety population) in study 2303	130
Table 97: Number (%) of patients with common AEs (at least 1% in total) by preferred term during the double-blind period (Safety population) in study 2303.....	131
Table 98: Number (%) of patients with adverse events leading to discontinuation during the double-blind period by preferred term and randomized treatment group (Safety population) in study 2303	131
Table 99: Duration of exposure to study drug in active-controlled treatment period by dose level (Randomized population) in study 2306.....	133
Table 100: Adverse events leading to discontinuation in active-controlled treatment period by preferred term and treatment group (safety population) in study 2306	135

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

Table 101: Adverse events leading to discontinuation in placebo-controlled treatment withdrawal period by preferred term and treatment group (withdrawal safety population) in study 2306	135
Table 102: Number (%) of patients with common adverse events (> or = 2% in any treatment group) in active-controlled treatment period by the order of the frequency (safety population) in study 2306	136
Table 103: Number (%) of patients with common adverse events (> or = 2% in any treatment group) in placebo-controlled treatment withdrawal period (withdrawal safety population) in study 2306	136
Table 104: Between-treatment analysis for change from baseline in msDBP at Week 8 endpoint (intent-to-treat population) in study 2309	138
Table 105: Between-treatment analysis for change from baseline in msSBP at Week 8 endpoint (intent-to-treat population)	138
Table 106: Duration of exposure to study medication during the double-blind treatment period by treatment group in study 2309	139
Table 107: Number (%) of patients with common adverse events ($\geq 2.0\%$) starting in double-blind period in any treatment group by the order of frequency (safety double-blind population) in study 2309	140
Table 108: Number (%) of patients with SAEs during double-blind treatment period by preferred term and treatment group (safety double-blind population) in study 2309	141
Table 109: Adverse events starting in double-blind treatment period and leading to study drug discontinuation by system organ class and treatment group (safety double-blind population)	142
Table 110: Number (%) of patients with orthostatic blood pressure during the double-blind treatment period (safety double-blind population) in study 2309	142
Table 111: Study design in study 1202	144
Table 112: Patient disposition and analysis set in study 1202	144
Table 113: Summary of mean sitting blood pressure results at end of treatment (Visit 16 or last observation carried forward) in all treated patients in study 1202	144
Table 114: Exposure to actual therapy by interval during the entire study in study 1202	145
Table 115: Common AEs ($\geq 2\%$ in all treated patients) by actual therapy received- n (%) of patients (Safety population) in study 1202	146
Table 116: Serious adverse events in the actual therapy group (Safety population) in study 1202	146
Table 117: Adverse events leading to discontinuation in actually therapy (Safety population) in study 1202	147
Table 118: Biochemistry notable change from baseline by therapeutic group- n (%) of patients (safety population) in study 1202.	148
Table 119: Patient disposition and analysis populations in study 2331	150
Table 120: Number (%) of patients with adverse events (> or = 2.0%) starting in double-blind period in any treatment group (safety population) in study 2331	151
Table 121 : Number (%) of patients with adverse events leading to discontinuation by preferred term and treatment group (safety population) in study 2331	153

Clinical Review
Shen Xiao, M.D., Ph.D.
NDA 22-107; N-000
Aliskiren/hydrochlorothiazide (Tekturna HCT®)

List of Figures

Figure 1: The average of change from baseline in msDBP by time (four figures provided by sponsor)..... 30
Figure 2: Dose-response surface analysis for change in sitting BP at endpoint 32
Figure 3: Study design flow chart in Study 0014 100
Figure 4: Study 2204 Plan..... 111

Abbreviations

ACE	angiotensin converting enzyme
ACEI	angiotensin converting enzyme inhibitor
ABPM	ambulatory blood pressure monitoring
ADME	absorption, distribution, metabolism, and excretion
AE	adverse event
ALT	alanine aminotransferase (SGPT)
ANCOVA	analysis of covariance
ARB	angiotensin receptor blocker
AST	aspartate aminotransferases (SGOT)
AUC	area under the curve
BID	twice a day
BMI	body mass index
BP	blood pressure
BUN	blood urea nitrogen
CABG	coronary artery bypass graft
CAT	coaxial tomography
CK	creatinine kinase
CI	confidence interval
CMC	chemistry, manufacturing, and controls
CRF	case report form
CVA	cerebrovascular accident
DBP	diastolic blood pressure
DSI	Division of Scientific Investigation (FDA)
ECG	electrocardiogram
EEG	electroencephalogram
FDA	Food and Drug Administration
GCP	Good Clinical Practices
GFR	glomerular filtration rate
GI	gastrointestinal
GLP	Good Laboratory Practices
HbA1c	hemoglobin A1c
HGB	hemoglobin
HCTZ	hydrochlorothiazide
HF	heart failure
ICH	International Conference on Harmonization
IRB	institutional review board
ISE	Integrated Summary (Review) of Efficacy
ISS	Integrated Summary (Review) of Safety
ITT	intention-to-treat
LOCF	last observation carried forward
LSM	least squares mean
LVH	left ventricular hypertrophy
MI	myocardial infarction
MRI	magnetic resonance imaging

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

MSDBP	mean seated diastolic blood pressure
MSSBP	mean seated systolic blood pressure
NDA	New Drug Application
NOS	not otherwise specified
NS	not significant
OD	once a day
PD	pharmacodynamics
PEY	person-exposure-year
PK	pharmacokinetic
PRA	plasma renin activity
PRC	plasma renin concentration
PTCA	percutaneous coronary angioplasty
QD	once a day
QTc	QT interval corrected (for heart rate)
RAAS	renin-angiotensin-aldosterone system
RBC	red blood cells
SAE	serious adverse event
SAS	Statistical Analysis System
SBP	systolic blood pressure
SD	standard deviation
SE	standard error
SLE	systemic lupus erythromatosus
SPA	special protocol assessment
TIA	transient ischemic attack
ULN	upper limit of normal
US	United States

1 Executive Summary

1.1 Recommendation on Regulatory Action

From a clinical perspective I recommend that Tekturna HCT®, the combination of aliskiren and Hydrochlorothiazide (HCTZ), be approved for the treatment of hypertension. This combination product demonstrated clinically and statistically significant reductions in both diastolic and systolic blood pressure compared to placebo and each respective monotherapy in one randomized, double-blind, placebo-controlled trial and several other active-controlled trials. The maximum antihypertensive effect was generally attained after 4 weeks of therapy.

The adverse event profile of the combination is similar to each component monotherapy. The incidence of significant AEs identified during aliskiren monotherapy clinical development program including angioedema, and GI events are also similar in the aliskiren/HCTZ combination therapy. Regarding laboratory parameters, both aliskiren and HCTZ monotherapies increased the serum level of uric acids; the combination of aliskiren/HCTZ increased serum level of uric acid even further. There was no difference of incidence rates of gout and kidney stones in short-term studies. In the long-term open label study, however, the incidence rate of gout was 0.5% (4 cases) in the combination therapy and 0.1% (1 case) in the aliskiren monotherapy. Difference for the incidence of kidney stones was not observed in this long-term open label study although the higher serum level of uric acid was observed in the combination therapy. Overall, AE profile is considered to be acceptable for antihypertensive therapy.

1.2 Recommendation on Post-marketing Actions

1.2.1 Risk Management Activity

None

1.2.2 Required Phase 4 Commitments

None

1.2.3 Other Phase 4 Requests

b(4)

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

1.3 Summary of Clinical Findings

1.3.1 Brief Overview of Clinical Program

Aliskiren (Tekturna) is an inhibitor of renin, the enzyme that converts angiotensinogen to angiotensin I in the first and rate-limiting step of the renin-angiotensin-aldosterone system (RAAS). Aliskiren is the first and the only approved renin inhibitor so far.

Tekturna HCT® is a new combination product of Aliskiren with Hydrochlorothiazide (HCTZ) for the treatment of patients with hypertension. It is formulated as film-coated tablets for oral administration. The recommended doses of the combination of aliskiren/HCTZ included 150/12.5 mg; 150/25 mg; 300/12.5 mg; and 300/25 mg.

b(4)

The sponsor provided eight clinical studies in the original submission and one study in a later submission (120-day safety update) for the evaluation of efficacy and safety to support this combination product for the treatment of hypertension. These studies included one pivotal study, two short term active-controlled studies, two long-term open label studies and one long-term active-controlled study. Two other studies (conducted in Japan and Ireland, respectively) with small numbers of patients were also provided in the original submission. In the 120-day safety update, one short term active-controlled study was submitted for further safety evaluation. There were 2776 patients in the pivotal trial and a total of 7451 patients were evaluated in the safety database and extent of exposure.

1.3.2 Efficacy

The overall clinical design is to assess whether both monotherapy treatments contribute to the overall effect in blood pressure reduction of the combination treatment. There are a total of eight studies provided to support the efficacy claim. The Study SPP 100A 2204 is the pivotal study which provides a critical appraisal for the efficacy. Other studies provide efficacy support for both short term and long term use.

The primary endpoint was change from baseline in seated trough (i.e., prior to next treatment at the end of the 24-hour inter dosing interval) cuff diastolic blood pressure (DBP). Seated trough cuff systolic blood pressure (SBP), percent responders (DBP < 90 mmHg and/or ≥ 10 mmHg less than baseline), and control rate (SBP < 140 and DBP < 90 mmHg) were analyzed as the secondary endpoints.

In the pivotal study, the tested drugs and doses included 1) aliskiren 75, 150 or 300 mg monotherapy; 2) HCTZ 6.25, 12.5 or 25 mg monotherapy; 3) aliskiren 75 with HCTZ 6.25, 12.5 or 25 mg combination therapy; 4) aliskiren 150 with HCTZ 6.25, 12.5, or 25 mg combination therapy; 5) aliskiren 300 mg with HCTZ 12.5 or 25 mg combination therapy; and 6) the placebo.

The study results showed that a significant greater change from baseline in mean sitting DBP at Week 8 was observed with the combination therapy compared with aliskiren and HCTZ monotherapies. Most individual combinations of aliskiren/HCTZ generally produced clinically

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT[®])

and statistically significant reductions in the DBP compared to placebo and each respective monotherapy in the studied dose range ($P < 0.01$ to 0.0001) except the aliskiren/HCTZ 150/6.25 mg vs each monotherapy, and aliskiren/HCTZ 75/12.5 mg vs HCTZ 12.5 mg.

For the secondary endpoint of SBP in this pivotal study, the pairwise comparison showed that the combination of aliskiren/HCTZ generally produced a greater reduction of SBP at Week 8 from baseline, compared with the placebo and each monotherapy ($P < 0.02$ to 0.0001).

The dose-response relationship study showed that reduction in msDBP was positively related to the dose of both aliskiren and HCTZ. For the response rate (defined as $DBP < 90$ mmHg or fall in $DBP \geq 10$ mmHg compared to baseline) and the control rate (defined as $DBP < 90$ mmHg and $SBP < 140$ mmHg), all combinations containing aliskiren 150 or 300 mg with HCTZ 12.5 or 25 mg produced statistically greater effects than the corresponding monotherapy ($P < 0.05$), except for the aliskiren/HCTZ 150/12.5 mg.

There are similar reductions of BP between ages of < 65 years (no children were included) and ≥ 65 years, gender, and baseline obesity of $BMI < 30$ kg/m^2 and $BMI \geq 30$ kg/m^2 after the combined therapy.

There are two other short-term active-controlled studies, Study 2309 and Study 2303. In study 2309, aliskiren/HCTZ 300/25 mg produced a statistically significant reduction in msDBP and msSBP compared to HCTZ 25 mg alone ($P < 0.0001$) at the Week 8 endpoint. In Study 2303, aliskiren and lisinopril were tested with the addition of HCTZ in patients with uncomplicated severe hypertension. Both treatment regimens showed clinically significant reductions in msDBP and msSBP at all time points.

The assessment for long-term use of this product was conducted in a 12-month long-term open-label study (Study 2302) and its 4-month extension (Study 2302E1). In addition, a 26-week, active-controlled study (Study 2306) was conducted in patients with mild to moderate hypertension. In all of these three studies, there was no direct efficacy comparison between the monotherapy and the combination treatment. Patients who received the HCTZ add-on were those whose blood pressure was not adequately controlled by aliskiren monotherapy. This may demonstrate additional and sustained blood pressure reduction if the blood pressure could be controlled by the addition of HCTZ. Study results indicated that both combination therapy and monotherapy produced clinically meaningful reduction of msDBP and msSBP from baseline and maintained throughout the whole study duration.

A pooled analysis of efficacy data was not performed due to the differences in study design, patient characteristics and length of treatment. Due to the paucity of non-Caucasian patients in the studies, the subgroup analysis for race/ethnicity (Caucasian, Black, Asian, Native American, Pacific Islander, and Other) was not performed.

b(4)

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

1.3.3 Safety

Overall, the adverse events including the mortality rate, SAEs, common AEs, discontinuation rates due to AEs, etc., in the combination of aliskiren and HCTZ were generally comparable with each of monotherapy.

Orthostatic changes were comparable between the combination of aliskiren with HCTZ and each of monotherapy in the short-term studies. In the long-term studies, however, the incidence of patients with orthostatic changes at any visit was slightly higher in the combination therapy group than in the aliskiren monotherapy group (12% vs 8%). There was no comparison between the combined therapy group and HCTZ group.

As expected, hypokalemia with $K^+ < 3.5$ mmol/L was more common in the HCTZ monotherapy and HCTZ-containing combination groups than in placebo and aliskiren monotherapy groups. The incidence of hyperkalemia was low and similar between the monotherapy and the combination therapy patients. No patients discontinued due to abnormal potassium values.

Since both of aliskiren and HCTZ can increase the serum level of uric acid, larger mean increases from baseline in uric acid occurred with the aliskiren/HCTZ and ACEI/HCTZ groups compared with aliskiren and ACEI monotherapy in the long-term studies. There was no difference of incidence rates of gout and kidney stone in short-term studies. In the long-term open label study, however, the incidence rate of gout was 0.5% (4 cases) in the combination therapy and 0.1% (1 case) in the aliskiren monotherapy. Difference for the incidence of kidney stone was not observed in this long-term open label study.

The incidence rate of other important AEs which were found in aliskiren monotherapy (NDA 21-985) including diarrhea, cough, angioedema, and slight decreases in hemoglobin and related parameters were similar or lower in the combination monotherapy compared to the aliskiren monotherapy.

Based on the provided short- and long-term studies, the AE profile with this combination product is considered to be acceptable for antihypertensive therapy.

1.3.4 Dosing Regimen and Administration

Tekturna HCT®, the combination of aliskiren with HCTZ, should be indicated for the treatment of hypertension. The fixed combinations may be used as replacement therapy for the titrated components. In addition, a patient whose blood pressure is not adequately controlled with aliskiren alone or HCTZ alone may switch to aliskiren/HCTZ daily treatment.

The sponsor proposed 4 fixed dosage strengths: 150/12.5 mg, 150/25 mg, 300/12.5 mg, and 300/25 mg. Based on the pivotal study, all of these four fixed doses produced clinically and statistically significant reductions in both msDBP and msSBP compared to placebo and each respective monotherapy at the same dose levels. In the safety analysis, the adverse event profile of these combination is similar to each component monotherapy. Therefore, it is reasonable to

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

approve all of these 4 dosages. The dosage may be started with the 150/12.5 mg and titrated to a maximum of one 300/25 mg tablet once daily.

1.3.5 Drug-Drug Interactions

In the 120-day safety update, the sponsor provided a new study (study 2331) for the comparison of triple combination of aliskiren/valsartan/HCTZ with the combination studies of aliskiren/HCTZ and valsartan/HCTZ as well as the monotherapy of HCTZ alone.

b(4)

No other drug-drug interaction studies were conducted.

1.3.6 Special Populations

Aliskiren/HCTZ was effective regardless of gender, age, and disease factor of obesity. Regarding the race/ethnicity, however, due to the paucity of non-Caucasian patients in the studies, the subgroup analysis for race/ethnicity (Caucasian, Black, Asian, Native American, Pacific Islander, and Other) was not performed. Children were not studied, and the Division granted a deferral of pediatric studies for the severe hypertension indication.

Studies of either aliskiren monotherapy or the combination of aliskiren with HCTZ were not conducted in pregnant women. The sponsor is proposing a black box warning in the label regarding use in pregnancy as is currently included in the labels for ACEIs and ARBs. There are three pregnant cases in the studies. While there have not been definite fetal abnormalities reported following these pregnancies, the experience with human pregnancies is obviously limited.

2 Introduction and Background

2.1 Product Information

Tekturna HCT® is a new combination product of Aliskiren with Hydrochlorothiazide (HCTZ). Aliskiren is a novel anti-hypertensive agent, which acts by inhibiting the enzyme renin to block the conversion of angiotensinogen to angiotensin I (Ang I), the precursor of angiotensin II (Ang II). Hydrochlorothiazide (HCTZ) is a thiazide diuretic, widely used to treat hypertension, especially with other agents. Thiazides inhibit renal tubular re-absorption and thereby increase sodium chloride and water excretion and lower plasma volume, which, in turn, lowers BP. Tekturna HCT® is expected to provide more optimal blood pressure control than the component monotherapies through the complementary effects of the two drugs. This fixed-dose combination

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

tablet of aliskiren/HCTZ was developed for use in the targeted population of patients with essential hypertension at all ages.

Tekturna HCT® is a biconvex ovaloid film-coated tablet with different colors and labelings based on the dosage. White tablet imprinted with "LCI" on one side and "NVR" on the other side means 150/12.5 mg; pale yellow tablet imprinted with "CLL" on one side and "NVR" on the other side means 150/25 mg; violet white tablet imprinted with "CVI" on one side and "NVR" on the other side means 300/12.5 mg; light yellow tablet imprinted with "CVV" on one side and "NVR" on the other side means 300/25 mg.

2.2 Currently Available Treatment for Indications

Many drugs are approved for the treatment of hypertension. The most relevant approved drugs are those that also work by inhibiting the renin-angiotensin-aldosterone system (RAAS). RAAS inhibitors approved for hypertension include the newly approved renin inhibitor (Aliskiren), angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and aldosterone receptor antagonists (eplerenone, spironolactone). Aliskiren inhibits the conversion of angiotensinogen to angiotensin I by renin. ACEIs inhibit the conversion of angiotensin I to angiotensin II by ACE. ARBs block the action of angiotensin II at its receptor. Eplerenone and spironolactone block the effects of aldosterone, whose release is stimulated by angiotensin II.

Regarding the combination product, there are several products of fixed combination doses of ACEIs/HCTZ or ARBs/HCTZ available for the treatment of hypertension. There is no combination product of renin inhibitors/HCTZ on the market.

2.3 Availability of Proposed Active Ingredient in the United States

Aliskiren is approved as NDA 21-985 for monotherapy of the hypertension. Tekturna HCT® is not currently marketed in this country.

2.4 Important Issues With Pharmacologically Related Products

RAAS inhibitors share certain adverse events (AEs). Because all affect aldosterone, all can cause increases in serum potassium and hyperkalemia. All, either through effects on aldosterone or angiotensin II or both, can cause decreases in renal function. In addition to these AEs shared by all RAAS inhibitors, ACEIs cause cough, presumably through effects of ACE on the bradykinin pathway. ACEIs, and to a lesser extent ARBs, cause angioedema. Whether the latter is mediated through the bradykinin pathway is not clear. Some experts have hypothesized that renin inhibitors should not cause these latter AEs, but whether they do or don't has not been confirmed in clinical trials. Finally, ARBs have recently been implicated in rare cases of rhabdomyolysis.

Tekturna HCT® as a new combination of renin inhibitor and diuretics may have a relatively low incidence for some adverse effects caused by RAAS inhibitors such as hyperkalemia. However, HCTZ as a thiazide diuretics may cause some metabolic disorders related to glucose, uric acid, calcium, and potassium.

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

2.5 Pre-submission Regulatory Activity

At the end-of-phase II meeting on February 11, 2004 for the aliskiren development program, the Division agreed that the multi-factorial design study 2204 evaluating various combinations of Aliskiren with HCTZ can be considered a single, pivotal efficacy trial for the approval of an NDA for a fixed-dose combination of aliskiren with HCTZ with the addition of PK data.

On June 3, 2004, the Division sent a letter to the sponsor regarding a special protocol assessment (SPA) for Study 2204. The Division noted that the protocol did not include pharmacokinetic (PK) and/or pharmacodynamic (PD) assessments. The interaction between aliskiren and HCTZ should be evaluated in this study by using a sparse sampling approach. A blood sample for aliskiren assay should be collected as close as possible to the occurrence of the adverse event.

At the pre-NDA meeting for Tekturna HCT® submission on September 8, 2006, the Division sent a letter to the sponsor that the Division granted a waiver of pediatric assessments in the original NDA supporting the product.

2.6 Other Relevant Background Information

N/A

3 Significant Findings from Other Review Disciplines

3.1 CMC (and Product Microbiology, if Applicable)

The CMC reviewer, Dr. Xavier Ysern, judges this application approvable from the CMC perspective pending satisfactory responses to some questions regarding assays and batch reprocessing specifications. Other CMC issues appear to have been addressed adequately by the sponsor and are described well in the FDA CMC review. Please see the Chemistry review.

3.2 Animal Pharmacology/Toxicology

No preclinical pharmacodynamic or pharmacokinetic studies were performed with the new combination product. Toxicity studies were conducted with aliskiren and HCTZ as free combinations in the rat with dose range-finding and 13-week studies. The animal pharmacology and toxicology reviewer, Dr. G. Jagadeesh, judges this application approvable from the pharmacology and toxicology perspective. Please see Dr. Jagadeesh's review for the pre-clinical findings.

Clinical Review
Shen Xiao, M.D., Ph.D.
NDA 22-107; N-000
Aliskiren/hydrochlorothiazide (Tekturna HCT®)

4 Data Sources, Review Strategy, and Data Integrity

4.1 Sources of Clinical Data

The primary source of clinical data for this review was the initial NDA submission dated March 19, 2007. This submission included electronic study reports for studies SPP100A0014, SPP100A2204, SPP100A2302, SPP100A2302E1, SPP100A2303, SPP100A2306, SPP100A2309 and SPP100A1202.

In the 120-day safety update, the sponsor sent the electronic study report for study SPP 100A 2331 dated July 19, 2007.

4.2 Tables of Clinical Studies

The sponsor conducted eight clinical studies for the evaluation of efficacy and safety to support this combination product for the treatment of the primary hypertension in the initial submission. Three other studies are ongoing and data are not provided with original submission (table 2). One of these three studies (study 2331) was submitted later in a 120-day safety update. In addition, the sponsor has conducted PK, and bioavailability and bioequivalence studies in healthy volunteers with this combination product. Please see the FDA clinical pharmacologist's review for tabulations and reviews of those studies. Studies for efficacy and safety evaluation of this product included in this initial NDA are displayed in the following Table 1.

Appears This Way
On Original

Clinical Review
 Shen Xiao, M.D., Ph.D.
 NDA 22-107; N-000
 Aliskiren/hydrochlorothiazide (Tekturna HCT®)

Table 1: Studies Supporting Efficacy and Safety in Hypertension

(w: white, b: black, a: asia, o: others)

Studies	Total No & race	Dose (mg)	Duration	Design	Comment
#2204	2776 2372w 127b 69a 208 o	Aliskiren: 75, 150, 300 HCTZ: 6.25, 12.5, 25 Aliskiren/HCTZ: 75/6.25, 75/12.5, 75/25, 150/6.25, 150/12.5, 150/25, 300/12.5, 300/25	8-week	Double blind, multicenter, randomized multifactorial, placebo-controlled, parallel group study in patients with essential hypertension (msDBP \geq 95 mmHg and < 110 mmHg)	Pivotal study in multiple countries including US.
#2303	183 182w, 1o	Aliskiren: 150, 300 Aliskiren/HCTZ: 300/25 Lisinopril: 20, 40 Lisinopril/HCTZ: 40/25	8-week	Double blind, randomized, active controlled, parallel group study in patients with uncomplicated severe hypertension	Not in US
# 2309	489 487w, 2o	HCTZ: 25 Aliskiren/HCTZ: 150/25, 300/25 Irbesartan/HCTZ: 150/25, 300/25 Amlodipine/HCTZ: 5/10, 5/25	12-week	Double blind, parallel group study in patients with BMI \geq 3kg/m ² in adequately responsive to HCTZ 25 mg.	Not in US Change from baseline in msDBP at week 8 as the primary endpoint
#2306	842 638w, 151b, 27a, 26o	Aliskiren: 300 Aliskiren/HCTZ: 300/12.5, 300/25 Ramipril: 10 Ramipril/HCTZ: 10/12.5, 10/25	26-week	Double blind, randomized, multicenter, parallel group, active-controlled study over a period of 26 weeks following by a 4-week double blind, randomized placebo-controlled withdrawal.	Patients were titrated after 6 weeks and randomized withdrawal.
#2302	1955 1687w 115b, 15a, 138o	Aliskiren 75, 150, 300 HCTZ 12.5, 25 Aliskiren/HCTZ 300/12.5, 300/25	12 month	Open-label, multicenter, study to assess the long-term effect of aliskiren with or without HCTZ.	
#2302E1	198 186w, 9b, 1a, 2o	Aliskiren/HCTZ 300/25	4 month	4 month high dose combination open label treatment	
#1202	344 a	Aliskiren 75, 150, 300 Aliskiren/calcium channel blocker Aliskiren/diuretic	44-week	Extension trial for Aliskiren monotherapy (#1201). Open label, parallel group, long-term treatment for essential hypertension	Conducted in Japan only
#0014	23w	Aliskiren 150 Aliskiren/HCTZ 150/25	6-week	Open label, randomized study to evaluate the effect of the combination of aliskiren and HCTZ.	Conducted only in Ireland

Clinical Review
 Shen Xiao, M.D., Ph.D.
 NDA 22-107; N-000
 Aliskiren/hydrochlorothiazide (Tekturna HCT®)

Table 2: Ongoing Studies to Support Efficacy and Safety in Hypertension

Studies	Total No & race	Dose (mg)	Duration	Design	Comment
#2331	641	HCTZ 25 Aliskiren/HCTZ 150/25, 300/25 Valsartan/HCTZ 160/25, 320/25 Aliskiren/Valsartan/HCTZ 150/160/25, 300/320/25	8-week	Randomized, double blinded, parallel group, multicenter comparing efficacy and safety study in patients not adequately responding to HCTZ	Ongoing and no result available (only in Europe)

[Redacted content]

b(4)

4.3 Review Strategy

I initially reviewed all of the eight trials as shown in table 1. I performed detailed reviews of the pivotal placebo-controlled trial (protocol CSPP100A 2204) for approval from an efficacy aspect. For an integrated review of safety, I relied primarily upon analyses of all of the trials from table 1 and study 2331 in the 120-day safety update.

4.4 Data Quality and Integrity

Since this NDA is a drug combination application and all of the studies have been conducted in nearly all of the same sites as the approved NDA 21-985 (Aliskiren monotherapy) where some of them have been audited by DSI, I do not think any additional audits are required.

From the provided dataset, I did not identify any problems or major discrepancy which might confound the efficacy and safety results of this NDA.

4.5 Compliance with Good Clinical Practices

Based on the sponsor's claims, all studies were conducted in full compliance with Good Clinical Practice and in accordance with the following directives:

1. Declaration of Helsinki and amendments, concerning medical research in humans (Recommendations Guiding Physicians in Biomedical Research Involving Human Patients).
2. Directive 91/507/EEC: The Rules Governing Medicinal Products in the European Community.

Clinical Review
Shen Xiao, M.D., Ph.D.
NDA 22-107; N-000
Aliskiren/hydrochlorothiazide (Tekturna HCT®)

3. US 21 Code of Federal Regulations dealing with clinical studies, parts 50 and 56, concerning informed patient consent and Institutional Review Board approval.

4.6 Financial Disclosures

The sponsor provided a detailed lists of all the clinical investigators participating in studies SPH100A2101, SPH100A2102, SPH100A2103, SPH100A2104, SPP100A2204, SPP100A2302, SPP100A2302E1, SPP100A2303, SPP100A2306, SPP100A2309, SPP100A1202 conducted at US and non-US sites. From the list, one investigator from study 2306 reported "Grants, Honoraria, Travel Expenses" exceeding \$25,000. The first four studies (2101, 2102, 2103 and 2104) are clinical pharmacology, bioavailability and bioequivalence studies.

This one potential conflicts of interest should not prejudice the results greatly even if there were overt manipulation.

5 Clinical Pharmacology

Since this NDA is a combination of two approved drugs, a bridge pharmacokinetic drug-drug interaction study with aliskiren and HCTZ was conducted. This study was performed in healthy subjects and summarized in section 5.1 (below). For more details see the FDA clinical pharmacology review.

5.1 Pharmacokinetics

The study was an open label, two-period, multiple dose trial to investigate pharmacokinetic drug-drug interaction potential between aliskiren and HCTZ following multiple oral dose administration in healthy subjects.

Twenty-two (22) healthy volunteers participated in the study. In Period 1 (study days 1-4), subjects received a single 25 mg daily dose of HCTZ. Period 1 was followed by a 4-day washout period (study days 5-8). In Period 2 (study days 9-19), subjects received aliskiren 300 mg once a day for a total of 11 days (study days 9-19), with a single 25 mg daily dose of HCTZ co-administered for 4 days (study days 16-19). All drug administration was conducted under fasted conditions.

Pharmacokinetic parameters of aliskiren and HCTZ at steady-state are summarized in table 3 and table 4 (provided by sponsor), respectively. As shown in the following tables, although there was a moderate decrease in steady-state C_{max} (see ratio of geometric means) when two drugs were co-administered as compared to either drug alone, the steady-state overall exposure (AUC_τ) was nearly identical and the 90% CIs of the geometric mean ratios were all contained within 80-125% bioequivalent limits. Therefore, there was no significant pharmacokinetic interaction between aliskiren and HCTZ when co-administered as compared to administration of either drug alone.

Clinical Review
 Shen Xiao, M.D., Ph.D.
 NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

Table 3: Mean plus/minus SD (CV%) pharmacokinetic parameters of aliskiren at steady-state following single daily oral administration of 300 mg aliskiren alone (study day 15) or in combination with 25 mg HCTZ daily oral administration (study day 19)

Treatment	C _{max} (ng/ml)	t _{max} (h)	C _{min} (ng/ml)	AUC _T (h·ng/mL)
Aliskiren alone	425 ± 216 (51%)	2.2 (0.5, 6.0)	35 ± 13 (36%)	2310 ± 934 (40%)
Aliskiren + HCTZ	309 ± 150 (49%)	1.5 (0.5, 4.4)	41 ± 20 (47%)	2210 ± 1157 (52%)
Ratio of geometric means	0.78	NA	NA	0.93
90% confidence intervals	0.64 - 0.95	NA	NA	0.83 - 1.05

t_{max} = median (min, max)

Table 4: Mean plus/minus SD (CV%) pharmacokinetic parameters of HCTZ at steady-state following single daily oral administration of 25 mg HCTZ alone (study day 4) or in combination with 300 mg aliskiren daily oral administration (study day 19)

Treatment	C _{max} (ng/ml)	t _{max} (h)	C _{min} (ng/ml)	AUC _T (h·ng/mL)
HCTZ alone	260 ± 86 (33%)	1.5 (1.0, 4.0)	15 ± 6 (41%)	1411 ± 316 (22%)
HCTZ + Aliskiren	187 ± 43 (23%)	2.0 (1.0, 3.4)	20 ± 7 (36%)	1273 ± 297 (23%)
Ratio of geometric means	0.74	NA	NA	0.90
90% confidence intervals	0.69 - 0.79	NA	NA	0.87 - 0.93

t_{max} = median (min, max)

5.2 Pharmacodynamics

Study was not conducted.

5.3 Exposure-Response Relationships

Study was not conducted.

Clinical Review
Shen Xiao, M.D., Ph.D.
NDA 22-107; N-000
Aliskiren/hydrochlorothiazide (Tekturna HCT®)

6 Integrated Review of Efficacy

6.1 Indication

The indication for the proposed aliskiren/HCTZ fixed-dose combination tablets (Tekturna HCT) is the treatment of hypertension.

6.1.1 Methods

There are total eight studies were provided to support the efficacy claim as tabulated in Section 4.2.

The Study SPP 100A 2204 is the pivotal study which provides a critical appraisal for supporting the efficacy.

Study SPP 100A 2309 is an active-controlled study in obese patients not adequately responding to HCTZ monotherapy. Study SPP 100A 2303 is an active-controlled study in severe hypertensive patients with the open-label addition of HCTZ to aliskiren or lisinopri. Both of studies provide supportive efficacy information.

The long-term open label Study SPP 100A 2302 and its extension Study SPP 100A 2302 E, as well as the long term active-controlled Study SPP100A 2306 support the long term efficacy. In addition, two studies conducted in Japan (Study SPP 100A 1202) and Ireland (Study SPP 100A0014) were also provided for efficacy information.

For the primary evaluation of efficacy, my review focuses on the Study SPP 100A 2004 for the initial evaluation of the antihypertensive effects. I then examine results of the other studies to answer other critical questions such as the long term effect, population variation, subgroup analysis, etc.

6.1.2 General Discussion of Endpoints

The primary endpoint in the pivotal study (SPP 100A 2204) and other two large, multicenter, randomized, double-blind, controlled, parallel group trials (SPP 100A 2309 and SPP 100A 2306) was change from baseline in seated trough (i.e., prior to next treatment at the end of the 24-hour inter dosing interval) cuff diastolic blood pressure (DBP). Seated trough cuff systolic blood pressure (SBP), percent responders (DBP < 90 mmHg and/or ≥ 10 mmHg less than baseline), and control rate (SBP < 140 and DBP < 90 mmHg) were analyzed as second secondary endpoints. The proportion of responders and the control rate were analyzed by means of a logistic regression model with treatment and region as factors, and baseline DBP as a covariate. In addition, ambulatory blood pressure measurement (ABPM) was done in Study SPP 100A 0014 to justify the once daily dosing.

Clinical Review
Shen Xiao, M.D., Ph.D.
NDA 22-107; N-000
Aliskiren/hydrochlorothiazide (Tekturna HCT[®])
6.1.3 Study Design

The overall clinical design in this program is to assess whether both monotherapy treatments contribute to the overall effect in blood pressure reduction of the combination treatment. The clinical studies in this program included patients with mild to moderate essential hypertension (mean diastolic pressure ≥ 90 or 95 and < 110 mmHg), except for study CSPP100A 2303, which recruited patients with severe hypertension (diastolic pressure ≥ 105 and < 120 mmHg).

The baseline demographic characteristics of the treatment groups were comparable within each study, and were generally comparable across the different studies except for differences specified in the protocols: baseline blood pressure was higher in study 2303 as it enrolled severe hypertensive patients and baseline body weight and BMI (≥ 30 kg/m²) are greater in study 2309 as it enrolled obese patients.

The dose selection in the combination was based on aliskiren monotherapy clinical trial data and the available marketed doses of HCTZ that are commonly used for the treatment of hypertension.

Study CSPP100A 2204 serves as the pivotal efficacy trial for this submission. It was a placebo-controlled, 4x4 factorial design study in patients with mild to moderate hypertension. This study included a 1-week washout, 2 to 4-week single-blind placebo run-in, and 8-week double-blind treatment. The primary endpoint, change from baseline in seated trough cuff DBP, was analyzed by a two-way analysis of covariance (ANCOVA) with treatment and region as factors, and baseline as a covariate. A statistical adjustment for multiple comparisons using Dunnett's procedure was used for studies including multiple aliskiren doses. The key secondary efficacy endpoint, change from baseline in seated trough cuff SBP, was similarly analyzed. The tested doses included 1) aliskiren 75, 150 or 300 mg monotherapy; 2) HCTZ 6.25, 12.5 or 25 mg monotherapy; 3) aliskiren 75 with HCTZ 6.25, 12.5 or 25 mg combination therapy; 4) aliskiren 150 with HCTZ 6.25, 12.5, or 25 mg combination therapy; 5) aliskiren 300 mg with HCTZ 12.5 or 25 mg combination therapy; and 6) the placebo. The primary objectives are to evaluate the aliskiren monotherapy in comparison to placebo and to evaluate the combinations of aliskiren and HCTZ in comparison to the component monotherapy. The final selection of the recommended dose for the fixed-dose combination of aliskiren/HCTZ was based on the results of this pivotal study.

In addition to the study 2204, other studies also provided supportive efficacy information in subgroups of the study population and the long-term efficacy information. For the details of the study designs and the individual study results, please see Appendix 10.1.

6.1.4 Efficacy findings

6.1.4.1 Primary Endpoint (DBP) and Major Secondary Endpoints

The changes from baseline for seated trough cuff DBP in the pivotal study (Study CSPP 100A 2204) were summarized in the following table 5. The data showed that, a significantly greater change from baseline in the mean sitting DBP at Week 8, compared with aliskiren and HCTZ

Clinical Review
 Shen Xiao, M.D., Ph.D.
 NDA 22-107; N-000
 Aliskiren/hydrochlorothiazide (Tekturna HCT®)

monotherapies. Most individual combinations of aliskiren/HCTZ generally produced clinically and statistically significant reductions in the DBP compared to placebo and each respective monotherapy in the studied dose range except the aliskiren/HCTZ 150/6.25 mg vs each monotherapy, and aliskiren/HCTZ 75/12.5 mg vs HCTZ 12.5 mg. However, the effect size is small for aliskiren between 75 and 150 mg and they are not differentiated. The dosages of HCTZ alone are also not differentiated. Note the substantial placebo effect. (nearly 7 mm Hg.)

Table 5: Sponsor's change from baseline in mean sitting diastolic blood pressure (mmHg) at endpoint (ITT population)

Monotherapy	N	LSM change from Baseline (SE)	Combination therapy	N	LSM change from Baseline (SE)
Aliskiren 75 mg	183	-8.68 (0.59)	Aliskiren 75 mg/HCTZ 6.25 mg	187	-10.76 (0.59)
Aliskiren 150 mg	183	-8.94 (0.59)	Aliskiren 75 mg/HCTZ 12.5 mg	189	-11.14 (0.59)
Aliskiren 300 mg	180	-10.26 (0.60)	Aliskiren 75 mg/HCTZ 25 mg	186	-11.46 (0.59)
HCTZ 6.25 mg	194	-9.07 (0.58)	Aliskiren 150 mg/HCTZ 6.25 mg	173	-10.38 (0.61)
HCTZ 12.5 mg	188	-10.11 (0.59)	Aliskiren 150 mg/HCTZ 12.5 mg	184	-11.90 (0.59)
HCTZ 25 mg	173	-9.37 (0.61)	Aliskiren 150 mg/HCTZ 25 mg	187	-12.65 (0.59)
Placebo	192	-6.93 (0.58)	Aliskiren 300 mg/HCTZ 12.5 mg	180	-13.87 (0.60)
			Aliskiren 300 mg/HCTZ 25 mg	173	-14.26 (0.61)

Pairwise Comparison	LSM difference			
	Change from Baseline (SE)	95% CI	Nominal p-value	
Aliskiren 75 mg vs. placebo	-1.75 (0.83)	(-3.37, -0.13)	0.0344*	
Aliskiren 150 mg vs. placebo	-2.01 (0.83)	(-3.63, -0.39)	0.0152*	
Aliskiren 300 mg vs. placebo	-3.33 (0.83)	(-4.95, -1.70)	< 0.0001*	
Aliskiren 75 mg/HCTZ 6.25 mg	vs. aliskiren 75 mg	-2.08 (0.83)	(-3.71, -0.45)	0.0126*
	vs. HCTZ 6.25 mg	-1.69 (0.82)	(-3.30, -0.08)	0.0394*
	vs. placebo	-3.83 (0.82)	(-5.44, -2.22)	< 0.0001*
Aliskiren 75 mg/HCTZ 12.5 mg	vs. aliskiren 75 mg	-2.46 (0.83)	(-4.09, -0.83)	0.0031*
	vs. HCTZ 12.5 mg	-1.03 (0.83)	(-2.65, 0.59)	0.2124
	vs. placebo	-4.21 (0.82)	(-5.82, -2.60)	< 0.0001*
Aliskiren 75 mg/HCTZ 25 mg	vs. aliskiren 75 mg	-2.77 (0.83)	(-4.41, -1.14)	0.0009*
	vs. HCTZ 25 mg	-2.09 (0.85)	(-3.75, -0.43)	0.0136*
	vs. placebo	-4.52 (0.82)	(-6.14, -2.91)	< 0.0001*
Aliskiren 150 mg/HCTZ 6.25 mg	vs. aliskiren 150 mg	-1.41 (0.85)	(-3.08, 0.25)	0.0962
	vs. HCTZ 6.25 mg	-1.29 (0.84)	(-2.93, 0.36)	0.1249
	vs. placebo	-3.42 (0.84)	(-5.07, -1.78)	< 0.0001*
Aliskiren 150 mg/HCTZ 12.5 mg	vs. aliskiren 150 mg	-2.96 (0.84)	(-4.60, -1.32)	0.0004*
	vs. HCTZ 12.5 mg	1.79 (0.83)	(-3.42, -0.16)	0.0314*
	vs. placebo	-4.97 (0.83)	(-6.59, -3.35)	< 0.0001*
Aliskiren 150 mg/HCTZ 25 mg	vs. aliskiren 150 mg	-3.70 (0.83)	(-5.33, -2.07)	< 0.0001*
	vs. HCTZ 25 mg	-3.28 (0.85)	(-4.94, -1.62)	0.0001*
	vs. placebo	-5.71 (0.82)	(-7.33, -4.10)	< 0.0001*
Aliskiren 300 mg/HCTZ 12.5 mg	vs. aliskiren 300 mg	-3.61 (0.84)	(-5.26, -1.95)	< 0.0001*
	vs. HCTZ 12.5 mg	-3.76 (0.84)	(-5.39, -2.12)	< 0.0001*
	vs. placebo	-6.93 (0.83)	(-8.56, -5.31)	< 0.0001*
Aliskiren 300 mg/HCTZ 25 mg	vs. aliskiren 300 mg	-4.00 (0.85)	(-5.68, -2.33)	< 0.0001*
	vs. HCTZ 25 mg	-4.90 (0.86)	(-6.59, -3.21)	< 0.0001*
	vs. placebo	-7.33 (0.84)	(-8.98, -5.68)	< 0.0001*

SE = Standard Error; LSM = Least Squares Mean; CI = Confidence Interval

Clinical Review

Shen Xiao, M.D., Ph.D.

NDA 22-107; N-000

Aliskiren/hydrochlorothiazide (Tekturna HCT®)

For the secondary endpoint of SBP in this pivotal study, the changes from baseline was summarized in the following table 6. The pairwise comparison showed that the combination of aliskiren/HCTZ generally produced a greater reduction of SBP at Week 8 from baseline, compared with the placebo and each monotherapy. There is also a substantial placebo effect (-7.5 mm Hg) as there was for DBP.

Table 6: Sponsor's change from baseline in mean sitting systolic blood pressure (mmHg) at endpoint (ITT population)

Monotherapy	N	LSM change from Baseline (SE)	Combination therapy	N	LSM change from Baseline (SE)
Aliskiren 75 mg	183	-9.37 (0.94)	Aliskiren 75 mg/HCTZ 6.25 mg	187	-14.29 (0.93)
Aliskiren 150 mg	183	-12.24 (0.94)	Aliskiren 75 mg/HCTZ 12.5 mg	189	-15.64 (0.93)
Aliskiren 300 mg	180	-15.74 (0.95)	Aliskiren 75 mg/HCTZ 25 mg	186	-17.32 (0.93)
HCTZ 6.25 mg	194	-10.95 (0.92)	Aliskiren 150 mg/HCTZ 6.25 mg	173	-15.31 (0.97)
HCTZ 12.5 mg	188	-13.92 (0.93)	Aliskiren 150 mg/HCTZ 12.5 mg	184	-17.61 (0.94)
HCTZ 25 mg	173	-14.30 (0.97)	Aliskiren 150 mg/HCTZ 25 mg	187	-19.47 (0.93)
Placebo	192	-7.48 (0.92)	Aliskiren 300 mg/HCTZ 12.5 mg	160	-19.82 (0.95)
			Aliskiren 300 mg/HCTZ 25 mg	173	-21.22 (0.97)

Pairwise Comparison	LSM difference			
	Change from Baseline (SE)	95% CI	Nominal p-value	
Aliskiren 75 mg vs. placebo	-1.89 (1.31)	(-4.46, 0.69)	0.1512	
Aliskiren 150 mg vs. placebo	-4.76 (1.31)	(-7.34, -2.18)	0.0003*	
Aliskiren 300 mg vs. placebo	-8.25 (1.32)	(-10.84, -5.67)	< 0.0001*	
Aliskiren 75 mg/HCTZ 6.25 mg	vs. aliskiren 75 mg	-4.93 (1.32)	(-7.52, -2.33)	0.0002*
	vs. HCTZ 6.25 mg	-3.34 (1.30)	(-5.90, -0.79)	0.0103*
	vs. placebo	-6.81 (1.31)	(-9.38, -4.25)	< 0.0001*
Aliskiren 75 mg/HCTZ 12.5 mg	vs. aliskiren 75 mg	-6.27 (1.32)	(-8.86, -3.69)	< 0.0001*
	vs. HCTZ 12.5 mg	-1.71 (1.31)	(-4.28, 0.85)	0.1905
	vs. placebo	-8.16 (1.30)	(-10.71, -5.60)	< 0.0001*
Aliskiren 75 mg/HCTZ 25 mg	vs. aliskiren 75 mg	-7.95 (1.32)	(-10.55, -5.36)	< 0.0001*
	vs. HCTZ 25 mg	-3.02 (1.34)	(-5.66, -0.39)	0.0246*
	vs. placebo	-9.84 (1.31)	(-12.40, -7.27)	< 0.0001*
Aliskiren 150 mg/HCTZ 6.25 mg	vs. aliskiren 150 mg	-3.07 (1.35)	(-5.71, -0.42)	0.0230*
	vs. HCTZ 6.25 mg	-4.36 (1.33)	(-6.97, -1.75)	0.0011*
	vs. placebo	-7.83 (1.33)	(-10.44, -5.21)	< 0.0001*
Aliskiren 150 mg/HCTZ 12.5 mg	vs. aliskiren 150 mg	-5.37 (1.33)	(-7.97, -2.77)	< 0.0001*
	vs. HCTZ 12.5 mg	-3.69 (1.32)	(-6.27, -1.10)	0.0052*
	vs. placebo	-10.13 (1.31)	(-12.70, -7.56)	< 0.0001*
Aliskiren 150 mg/HCTZ 25 mg	vs. aliskiren 150 mg	-7.23 (1.32)	(-9.82, -4.64)	< 0.0001*
	vs. HCTZ 25 mg	-5.17 (1.34)	(-7.81, -2.54)	0.0001*
	vs. placebo	-11.99 (1.31)	(-14.55, -9.43)	< 0.0001*
Aliskiren 300 mg/HCTZ 12.5 mg	vs. aliskiren 300 mg	-4.08 (1.34)	(-6.71, -1.45)	0.0024*
	vs. HCTZ 12.5 mg	-5.89 (1.33)	(-8.49, -3.29)	< 0.0001*
	vs. placebo	-12.33 (1.32)	(-14.92, -9.75)	< 0.0001*
Aliskiren 300 mg/HCTZ 25 mg	vs. aliskiren 300 mg	-5.48 (1.35)	(-8.14, -2.83)	< 0.0001*
	vs. HCTZ 25 mg	-6.92 (1.37)	(-9.60, -4.24)	< 0.0001*
	vs. placebo	-13.74 (1.33)	(-16.35, -11.1)	< 0.0001*

SE = Standard Error; LSM = Least Squares Mean; CI = Confidence Interval